Yuan Yuan, MD, PhD

Experts discuss the potential of antibody-drug conjugates in treating triple-negative breast cancer, highlighting ongoing trials and emerging therapies.

Experts discuss the critical unmet needs in triple-negative breast cancer, highlighting innovative treatments and the importance of developing effective biomarkers.

Explore effective strategies for managing side effects of ADC therapy in triple-negative breast cancer, focusing on toxicity and patient care.

Experts discuss the sequencing of antibody-drug conjugates in breast cancer treatment, exploring optimal strategies and emerging clinical data.

Explore the promising role of trastuzumab deruxtecan in treating HER2-low triple-negative breast cancer, highlighting key trial findings and expert insights.

It seems there is no text provided for summarization. Please share the content you'd like summarized, and I'll be happy to help!

Dr. Tarantino discusses the promising results of the Trodelvy breast cancer study, highlighting its impact on treatment for high-risk patients.

Dr. Yuan discusses the ASCENT-03 trial's efficacy, crossover implications, and safety data for sacituzumab govitecan in cancer treatment.

It seems there is no text provided for summarization. Please provide the text you'd like summarized, and I'll be happy to help!

It seems there is no text provided for summarization. Please provide the text you'd like summarized, and I'll be happy to help!

Explore the latest advancements in clinical trials for early-stage triple-negative breast cancer, focusing on promising antibody-drug conjugates (ADCs).

Discover the promising advancements in TROP2-targeted antibody-drug conjugates for treating triple-negative and hormone-positive breast cancer.

Explore the evolving treatment landscape for early-stage triple-negative breast cancer, highlighting innovative therapies and clinical trial insights.

Explore the evolving treatment landscape for early-stage triple-negative breast cancer, highlighting innovative therapies and clinical trial insights.

Explore the latest advancements in antibody-drug conjugates for treating triple-negative breast cancer, addressing critical challenges and innovations.

Yuan Yuan, MD, PhD, discussed the evolving landscape of therapeutic targets and payloads for ADCs in HER2-positive breast cancer.

Yuan Yuan, MD, PhD, discusses questions regarding the potential benefit of T-DXd in first line regimens for HER2-positive breast cancer with CNS metastases.

Yuan Yuan, MD, PhD, discusses a new treatment approach involving induction T-DXd followed by trastuzumab/pertuzumab maintenance in HER2-positive disease.

Yuan Yuan, MD, PhD, discusses the importance of optimizing dual-pathway targeting in ER-positive, HER2-positive metastatic disease.

Yuan Yuan, MD, PhD, reports the intracranial efficacy of T-DXd plus pertuzumab in HER2-positive breast cancer, per results from the DESTINY-Breast12 study.

Yuan Yuan, MD, PhD, discusses T-DXd plus pertuzumab in first-line HER2-positive advanced/metastatic breast cancer.

Yuan Yuan, MD, PhD, discusses radiation therapy approaches across various of breast cancer subtypes.

Yuan Yuan, MD, PhD, discusses key research evaluating adjuvant CDK4/6 inhibition in breast cancer.

Yuan Yuan, MD, PhD, discusses the potential shift towards minimizing surgical intervention for lymph node management in breast cancer.

Yuan Yuan, MD, PhD, discusses ongoing investigations at Cedars-Sinai of treatment de-escalation in patients with early-stage triple-negative breast cancer according to their pathological response.

Yuan Yuan, MD, PhD, discusses the importance of clinical trial participation and enrollment in patients with breast cancer.